Wishart G C, Plumb J A, Going J J, McNicol A M, McArdle C S, Tsuruo T, Kaye S B
CRC Department of Medical Oncology, University of Glasgow, UK.
Br J Cancer. 1990 Nov;62(5):758-61. doi: 10.1038/bjc.1990.373.
We have investigated P-glycoprotein (P-gp) expression in samples of primary breast cancer from 29 patients before therapy. We employed immunohistochemical techniques using two monoclonal antibodies (C219 and MRK16) and an indirect alkaline phosphatase method. Heterogeneous expression in epithelial cells was detected with both C219 (21 of 29) and MRK16 (16 of 29). A surprising finding was P-glycoprotein expression in stromal cells with both C219 (26 of 29) and MRK16 (12 of 29). Our results suggest that significant levels of P-glycoprotein expression may be present in breast cancer before exposure to drugs associated with multidrug resistance.
我们研究了29例原发性乳腺癌患者治疗前样本中P-糖蛋白(P-gp)的表达情况。我们采用免疫组织化学技术,使用两种单克隆抗体(C219和MRK16)及间接碱性磷酸酶法。C219(29例中的21例)和MRK16(29例中的16例)均检测到上皮细胞中的异质性表达。一个惊人的发现是,C219(29例中的26例)和MRK16(29例中的12例)均在基质细胞中检测到P-糖蛋白表达。我们的结果表明,在接触与多药耐药相关的药物之前,乳腺癌中可能存在显著水平的P-糖蛋白表达。